Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025)
Silence Therapeutics (SLN) posted Other Operating Expenses of -$4.0 million for Q2 2025, up 85.95% sequentially from -$28.4 million in Q1 2025, and up 78.62% YoY from -$2.2 million in Q2 2024.
Powered by 
Analysis
Silence Therapeutics (SLN) Other Operating Expenses (2024 - 2025) Analysis & Trends
Silence Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at -$4.0 million in Q2 2025.
- Quarterly Other Operating Expenses rose 78.62% year-over-year to -$4.0 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was -$4.0 million (up 91.52% YoY) and the FY2024 annual result came in at -$113.6 million, changed N/A from the prior year.
- Other Operating Expenses grew to -$4.0 million in Q2 2025 per SLN's latest filing, from -$28.4 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at -$4.0 million in Q2 2025 and troughed at -$28.4 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Silence Therapeutics | 689.65 Mn | 617.55 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -20.72 Mn |
| Mar 31, 2025 | -28.38 Mn |
| Jun 30, 2024 | -24.67 Mn |
| Mar 31, 2024 | -21.99 Mn |